HBW Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: OTC colloidal silver products

This article was originally published in The Rose Sheet

Executive Summary

OTC colloidal silver products: Deemed not safe and effective by FDA in a proposed rule published in the Oct. 15 Federal Register. FDA states in the rule that "there is a lack of adequate data to establish general recognition of the safety and effectiveness of colloidal silver ingredients or silver salts for OTC use." Some products containing colloidal silver have been marketed as treatments for skin conditions including acne and warts. FDA is requesting comments on whether colloidal silver products should be granted GRAS/E (generally recognized as safe and effective) status within 90 days...
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS003345

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel